Pharmachem Consultech India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.35 M
- Company Age 28 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -13.53%
- Profit Growth 30.63%
- Ebitda 107.02%
- Net Worth 22.66%
- Total Assets 21.70%
About Pharmachem Consultech India
Pharmachem Consultech India Private Limited (PCIPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 May 1996 and has a history of 28 years and eight months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.35 M, as per Ministry of Corporate Affairs (MCA) records.
Desikan Varadan and Muthuswamy Iyer serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74220MH1996PTC099596
-
Company No.
099596
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 May 1996
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Pharmachem Consultech India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Muthuswamy Iyer
|
Director | 16-May-1996 | Current |
|
Desikan Varadan
|
Director | 16-May-1996 | Current |
Financial Performance of Pharmachem Consultech India.
Pharmachem Consultech India Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 13.53% decrease. The company also saw a substantial improvement in profitability, with a 30.63% increase in profit. The company's net worth Soared by an impressive increase of 22.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmachem Consultech India?
In 2021, Pharmachem Consultech India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Impeccabilis Consulting LlpMuthuswamy Iyer is a mutual person
-
Bhrahmarpanam Foods Private Limited
Muthuswamy Iyer is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pharmachem Consultech India?
Unlock and access historical data on people associated with Pharmachem Consultech India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmachem Consultech India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmachem Consultech India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.